Literature DB >> 34808234

Risk of Progression to Autoimmune Disease in Severe Drug Eruption: Risk Factors and the Factor-Guided Stratification.

Yoshiko Mizukawa1, Yumi Aoyama2, Hayato Takahashi3, Ryo Takahashi4, Tetsuo Shiohara5.   

Abstract

The identification of risk factors is key not only to uncover the pathogenesis of autoimmune disease but also to predict progression to autoimmune disease. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms is likely the best prototypic example for analyzing the sequential events. We conducted a retrospective study of 55 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms followed up for the possibility of later development of autoimmune disease ∼18 years after resolution. Nine patients progressed to autoimmune sequelae regardless of treatment. The generation of autoantibodies was preceded by 8 years in eight of the nine patients. The combination of increases in lymphocyte counts, severe liver damage, a rebound increase in globulin, persistent reactivations of Epstein‒Barr virus and human herpesvirus-6, and low IL-2 and IL-4 at the acute/subacute phases were significant risk factors for the future development of autoimmune disease. On the basis of these factors, we established a scoring system that can identify high-risk patients. When stratified these patients into three risk categories (low/intermediate/high), occurrence of autoimmune disease was exclusively detected in the high group. Our data represent a scoring system to identify patients at high risk of developing autoimmune disease, although a larger study is required to validate the scoring system.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34808234     DOI: 10.1016/j.jid.2021.11.008

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  3 in total

1.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

2.  Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease.

Authors:  Eisuke Katsuren; Kentaro Kohagura; Takanori Kinjyo; Ryo Zamami; Takuto Nakamura; Nanako Oshiro; Yoshitsugu Sunagawa; Kumiko Omine; Yuki Kudo; Yuki Shinzato; Tsukasa Osaki; Masayoshi Souri; Akitada Ichinose; Masanobu Yamazato; Akio Ishida; Yusuke Ohya
Journal:  CEN Case Rep       Date:  2022-08-09

Review 3.  Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions.

Authors:  Yumi Aoyama; Seiko Sugiyama; Takenobu Yamamoto
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.